论文部分内容阅读
[目的]评价卡培他滨联合奥沙利铂(XELOX方案)一线治疗老年晚期大肠癌的疗效和毒副反应。[方法]58例老年(≥65岁)晚期大肠癌患者,奥沙利铂130mg/m2,第1d静脉滴注;卡培他滨2000mg/(m2·d),每天2次口服,第1～14d,21d为1个周期。[结果]58例患者中CR3例,PR25例,SD14例,PD16例,有效率为48.28%。中位生存期为15.8个月,中位疾病进展时间为8.1个月。毒副反应主要为手足综合征、神经毒性、骨髓抑制、恶心、呕吐多为Ⅰ～Ⅱ度。[结论]卡培他滨联合奥沙利铂的方案疗效确切,毒副反应小,老年患者能耐受,能提高生活质量。
[Objective] To evaluate the efficacy and toxicity of capecitabine combined with oxaliplatin (XELOX) in the first-line treatment of elderly patients with advanced colorectal cancer. [Method] Fifty-eight elderly patients (≥65 years old) with advanced colorectal cancer were treated with oxaliplatin 130mg / m2 intravenously on the first day, capecitabine 2000mg / (m2 · d) orally twice daily, 14d, 21d for a cycle. [Results] Among the 58 patients, CR3, PR25, SD14 and PD16 had an effective rate of 48.28%. The median survival time was 15.8 months and the median disease progression time was 8.1 months. Toxic and side effects mainly hand-foot syndrome, neurotoxicity, bone marrow suppression, nausea, vomiting and more for Ⅰ ~ Ⅱ degrees. [Conclusion] The combination of capecitabine and oxaliplatin has definite curative effect, small toxic and side reaction, the elderly patients can tolerate, and can improve the quality of life.